PresentationGood afternoon, and welcome to the United Therapeutics Corporation Phase 3 TETON-2 Results Conference Call. My name is Drew, and I will be your conference operator today. [Operator Instructions] Please note that this call is being recorded. I would now like to turn the webcast over to Harry Silvers, Investor Relations Manager at United Therapeutics.Harrison SilversManager of Investor Relations Thank you, Drew. Good day, everyone. It is my pleasure to welcome you to the United Therapeutics Corpor ...

In this article, we will be taking a look at the 12 Best Performing Healthcare Stocks to Buy Right Now.Spending on healthcare in the US is predicted to hit $5.3 trillion this year, making it one of the largest in the world. Although it is frequently thought of as a defensive industry that fared better in unpredictable times, that has not been the case. Despite the general equities market’s 12% gain so far this year and its rise to record highs, the sector is down roughly 1% for the year.Over the last three ...

Danish biotech Genmab (GMAB) is in advanced discussions to acquire Merus (NASDAQ:MRUS), a Dutch drug developer targeting head and neck cancer, Bloomberg News reported on Sunday, citing people familiar with the matter. Having received takeover interest from several large biopharma ...

TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medica ...

BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss updates for the Company’s nomlabofusp clinical development program including data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, September 29, 2025 at 8:00 am EDT. Conference ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

BREAKING: Futures Loom With Tesla, Jobs And Possible Gov't Shutdown AheadBridgeBio Pharma (BBIO) said Sunday its heart-disease drug, Attruby, cut the risk of death almost in half in an exploratory study that one cardiologist says could be a game-changer for the disease.Attruby is approved to treat patients with cardiomyopathy due to transthyretin amyloidosis. In this condition, abnormal plaque called amyloid builds up on the heart, causing damage. Patients who took Attruby for 30 months had a 49% lower risk ...

Sep 28, 2025 11:13 AM Eastern Daylight Time Share New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Treatment with Vutrisiran Led to 37- 49% Lower Rates of Gastrointestinal Events, a Multisystem Manifestation of ATTR-CM, Across Multiple Treatment Groups, Compared to Placebo – Additional Analyses Reinforce Vutrisiran's Safety and Efficacy Profile as a Monotherapy and Illustrate Consistent Benefit from Treatment with Vutrisiran ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Jasper sec ...

It's unclear how long it's going to be before this company has a product to sell.The artificial intelligence (AI) revolution has the potential to alter just about every business operation for the better. One area where investors are extra excited about productivity improvements is the drug development business.The vast majority of experimental drugs that enter clinical trials never become marketable products, but by applying AI to the discovery process, Recursion Pharmaceuticals (RXRX 1.84%) plans to become ...